Gilead Sciences, Inc. (GILD) Expected to Post Earnings of $1.70 Per Share
Wall Street brokerages predict that Gilead Sciences, Inc. (NASDAQ:GILD) will announce earnings per share (EPS) of $1.70 for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Gilead Sciences’ earnings, with estimates ranging from $1.29 to $2.11. Gilead Sciences reported earnings per share of $2.70 during the same quarter last year, which would suggest a negative year over year growth rate of 37%. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 6th.
According to Zacks, analysts expect that Gilead Sciences will report full year earnings of $8.72 per share for the current financial year, with EPS estimates ranging from $8.36 to $9.17. For the next financial year, analysts forecast that the business will report earnings of $6.90 per share, with EPS estimates ranging from $6.03 to $8.04. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period last year, the business earned $2.75 earnings per share. The firm’s revenue for the quarter was down 13.2% compared to the same quarter last year.
GILD has been the topic of a number of recent research reports. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. Royal Bank of Canada assumed coverage on shares of Gilead Sciences in a research note on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target for the company. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Robert W. Baird restated an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Leerink Swann restated a “hold” rating and set a $74.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $85.92.
In related news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the completion of the transaction, the executive vice president now owns 113,237 shares in the company, valued at approximately $8,945,723. The disclosure for this sale can be found here. In the last quarter, insiders sold 446,819 shares of company stock worth $36,269,486. 1.30% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the business. Seizert Capital Partners LLC grew its position in shares of Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after purchasing an additional 27,547 shares in the last quarter. Investment Centers of America Inc. boosted its position in shares of Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after acquiring an additional 1,958 shares in the last quarter. Fagan Associates Inc. boosted its position in shares of Gilead Sciences by 2.6% during the 2nd quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after acquiring an additional 845 shares in the last quarter. Capital Asset Advisory Services LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $875,000. Finally, First PREMIER Bank boosted its position in shares of Gilead Sciences by 9.0% during the 2nd quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock worth $1,524,000 after acquiring an additional 1,787 shares in the last quarter. Hedge funds and other institutional investors own 74.38% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) traded up $0.75 during mid-day trading on Monday, reaching $73.77. The company had a trading volume of 7,698,200 shares, compared to its average volume of 9,360,261. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The firm has a market capitalization of $95,383.76, a P/E ratio of 7.62, a PEG ratio of -1.22 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 4.74 and a debt-to-equity ratio of 1.10.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.82%. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.69%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.